Therapeutic Response

CD20 + status confers therapeutic sensitivity to Rituximab in patients with Non-Hodgkin Lymphoma.

Statements

Source and description
Rituxan (rituximab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).
RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.
riTUXimab (S/C 1400mg) Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (84 day) for reimbursement as a treatment option for the maintenance treatment of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients who have responded to induction therapy.
riTUXimab (S/C 1400mg) Maintenance Therapy-56 day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.
RiTUXimab 375 mg/m2 Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) for reimbursement as a treatment option for the maintenance treatment (84 day) of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.